Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7331-7339

  Matthieu, Boisson ^a,b   Matthieu, Jacobs ^b,c   Nicolas, Grégoire ^b,c   Patrice, Gobin ^a,b   Srine, March ^a,b,c   William, Couet ^a,b,c   Olivier, Mimoza ^a,b,c  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ADULT; AEROSOL; AGED; ANALYTICAL PARAMETERS; ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; CONCENTRATION PROCESS; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; EPITHELIAL LINING FLUID LEVEL; EPITHELIUM; FEMALE; HUMAN; LUNG INFECTION; LUNG LAVAGE; MALE; NEBULIZATION; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; POPULATION; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; BLOOD; CHEMISTRY; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; EXTRACELLULAR FLUID; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; HALF LIFE TIME; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; STATISTICAL MODEL; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIOTRANSFORMATION; COLISTIN; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; EXTRACELLULAR FLUID; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, STATISTICAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84912101033     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03510-14     Document Type: Article

References (38)

1. Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R. 2005. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. 39:39-44. http://dx.doi.org/10.1345/aph.1E099.
2. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340:23-30.
3. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. 2008. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178:921-928. http://dx.doi.org/10.1164/rccm.200712-1804OC.
4. Conole D, Keating GM. 2014. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs 74:377-387. http://dx.doi.org/10.1007/s40265-014-0181-0.
5. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ. 2010. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 36:1147-1155. http://dx .doi.org/10.1007/s00134-010-1879-4.
6. Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier JC, Mimoz O, Couet W. 2010. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob. Agents Chemother. 54:3702-3707. http://dx.doi.org/10.1128/AAC.00411-10.
7. Yapa SWS, Li J, Porter CJ, Nation RL, Patel K, McIntosh MP. 2013. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob. Agents Chemother. 57:5087-5095. http://dx.doi .org/10.1128/AAC.01127-13.
8. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
9. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2013. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin. Infect. Dis. 58:139-141. http://dx.doi .org/10.1093/cid/cit680.
10. Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B. 2003. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit. Care Med. 31:2102-2106. http://dx.doi.org/10.1097/01.CCM.0000069734.38738.C8.
11. Couet W, Grégoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther. 89: 875-879. http://dx.doi.org/10 .1038/clpt.2011.48.
12. Gobin P, Lemaître F, Marchand S, Couet W, Olivier JC. 2010. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chroma-tography-tandem mass spectrometry (LC-MS/MS). Antimicrob. Agents Chemother. 54:1941-1948. http://dx.doi.org/10.1128/AAC.01367-09.
13. Marchand S, Frat JP, Petitpas F, Lemaître F, Gobin P, Robert R, Mimoz O, Couet W. 2010. Removal of colistin during intermittent haemodialysis in two critically ill patients. J. Antimicrob. Chemother. 65:1836-1837. http://dx.doi.org/10.1093/jac/dkq185.
14. Gontijo AV, Grégoire N, Lamarche I, Gobin P, Couet W, Marchand S. 2014. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob. Agents Chemother. 58:3950-3956. http://dx.doi.org/10.1128/AAC.02819-14.
15. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47:1766-1770. http://dx.doi.org/10 .1128/AAC.47.5.1766-1770.2003.
16. Bulitta JB, Bingölbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 13:201-211. http://dx.doi .org/10.1208/s12248-011-9257-x.
17. Grégoire N, Mimoz O, Mégarbane B, Comets E, Chatelier D, Lasocki S, Gauzit R, Balayn D, Gobin P, Marchand S, Couet W. 2014. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob. Agents Chemother. 58: 7324-7330. http://dx.doi.org/10.1128/AAC.03508-14.
18. Bauer RJ, Guzy S, Ng C. 2007. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J. 9:E60-E83. http://dx.doi.org/10.1208/aapsj0901007.
19. Bulitta JB, Landersdorfer CB. 2011. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J. 13:212-226. http://dx .doi.org/10.1208/s12248-011-9258-9.
20. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504. http://dx.doi .org/10.1023/A:1012299115260.
21. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112: 275-285. http://dx.doi.org/10.1172 /JCI200316814.
22. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651. http://dx.doi.org/10.1086/424849.
23. Campion JJ, McNamara PJ, Evans ME. 2005. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:209-219. http://dx.doi.org/10.1128/AAC.49.1.209 -219.2005.
24. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. 2010. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 138:1333-1339. http://dx.doi.org/10.1378/chest.10-0463.
25. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ. 2012. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 38:1779-1786. http://dx.doi.org/10.1007/s00134-012 -2628-7.
26. He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J. 2013. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J. Antimicrob. Chemother. 68: 2311-2317. http://dx.doi.org/10.1093/jac /dkt207.
27. rd Eur. Congr. Clin. Microbiol. Infect. Dis., 27 to 30 April 2013, Berlin, Germany.
28. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294. http://dx.doi .org/10.1128/AAC.01733-10.
29. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gramnegative bacteria. Antimicrob. Agents Chemother. 53:3430-3436. http: //dx.doi.org/10.1128/AAC.01361-08.
30. Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. 2011. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob. Agents Chemother. 55: 1606-1610. http://dx.doi.org/10.1128/AAC.01330-10.
31. Fernandes CA, Vanbever R. 2009. Preclinical models for pulmonary drug delivery. Expert Opin. Drug Deliv. 6:1231-1245. http://dx.doi.org/10.1517 /17425240903241788.
32. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. (1985) 60:532-538.
33. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. 2010. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob. Agents Chemother. 54:3783-3789. http://dx.doi.org/10.1128/AAC.00903-09.
34. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL. 2010. Elucidation of pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54: 1117-1124. http://dx.doi.org/10.1128/AAC.01114-09.
35. Dahyot C, Marchand S, Bodin M, Debeane B, Mimoz O, Couet W. 2008. Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Clin. Pharmacokinet. 47:181-189. http://dx.doi.org/10.2165/00003088-200847030-00004.
36. Liu P, Rand KH, Obermann B, Derendorf H. 2005. Pharmacokineticpharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int. J. Antimicrob. Agents 25:120-129. http://dx.doi.org/10.1016/j.ijantimicag.2004.09.012.
37. Marchand S, Dahyot C, Lamarche I, Mimoz O, Couet W. 2005. Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats. Antimicrob. Agents Chemother. 49: 2356-2361. http://dx.doi.org/10.1128/AAC.49.6.2356-2361.2005.
38. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob. Agents Chemother. 56: 4241-4249. http://dx.doi.org/10 .1128/AAC.06426-11.